Protocol Ledger

NCT07104565 · Phase II · RECRUITING

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Interventional Phase II clinical trial protocol NCT07104565 sponsored by Incyte in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-29 Enrollment: 56 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07104565
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)56 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07104565
Protocol FieldVerified Registry Value
NCT IdentifierNCT07104565
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment56 participants (ESTIMATED)
Registered Start Date2025-12-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI